Skip to main content
Torrent Pharmaceuticals Ltd. logo

Torrent Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · TORNTPHARM ISIN · INE685A01028 LEI · 335800NA6HK275RIJE13 BSE.NS Manufacturing
Open in API
Filings indexed 1,750 across all filing types
Latest filing 2026-05-22 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS TORNTPHARM

About Torrent Pharmaceuticals Ltd.

https://www.torrentpharma.com

Torrent Pharmaceuticals Ltd. is a research-driven organization focused on the development, manufacturing, and marketing of generic formulations. The company holds a significant position in therapeutic areas such as cardiovascular, central nervous system, gastrointestinal, diabetology, and anti-infective treatments. It has strategically expanded its portfolio into dermatology, nephrology, and pain management through targeted acquisitions. The firm operates across multiple international markets, supported by advanced research and development centers and manufacturing facilities that adhere to global regulatory standards. Its core operations prioritize chronic therapy leadership and the provision of high-quality healthcare solutions through a robust pipeline of generic and value-added medicines.

Recent filings

Filing Released Lang Actions
Dividend
Interim / Quarterly Report Classification · 77% confidence The document is the board meeting disclosure under SEBI LODR Regulation 30 and 33 providing the audited financial results (standalone and consolidated) for the quarter and year ended March 31, 2026 accompanied by the Independent Auditor’s Report. It contains comprehensive financial statements and data for the quarter (an interim period) rather than a full Annual Report. It is not merely a press release (ER) nor just an audit opinion (AR) alone. Therefore, it fits the definition of an Interim / Quarterly Report (IR). FY 2026
2026-05-22 English
Results for quarter and year ended 31-Mar-26
Interim / Quarterly Report Classification · 84% confidence The document is a formal SEBI Listing Regulations (Reg. 30 & 33) disclosure of audited financial results for the quarter and year ended March 31, 2026, including the Board’s approval, auditor’s unqualified report, detailed standalone profit & loss statement and recommended dividend/QIP proposal. It is not a full Annual Report (10-K) but a regulatory exchange filing of periodical results containing substantive financial data (P&L line items) and an auditor’s report. This corresponds to a comprehensive Interim/Quarterly Report (“IR”) rather than a mere earnings highlight (“ER”) or full annual report. FY 2026
2026-05-22 English
Newspaper advertisement in respect of transfer of shares to IEPF
Regulatory Filings Classification · 78% confidence The document is a statutory compliance notice under Section 124(6) of the Companies Act regarding transfer of unclaimed dividends and shares to the IEPF Authority. It is addressed to the stock exchanges, encloses newspaper cuttings, and serves as a regulatory announcement rather than a financial report, dividend notice or management discussion. This falls under general regulatory filings (RNS).
2026-05-21 English
Copy of Newspaper Publication
Regulatory Filings Classification · 90% confidence The document is a notice published in newspapers and filed with the stock exchanges regarding the statutory transfer of unclaimed dividends and corresponding shares to the Investor Education and Protection Fund under Section 124(6) of the Companies Act. It is a compliance/regulatory announcement rather than a financial report, management discussion, dividend declaration, or share issuance. Therefore, it falls under the general regulatory filings category.
2026-05-21 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 55% confidence The provided text is a notice to stock exchanges scheduling and rescheduling a teleconference with investors/analysts to discuss quarterly/year-end financial performance. It does not include any financial results, Q&A transcript, actual report content, or data but is purely a regulatory announcement of a conference call. It therefore falls under the generic “Regulatory Filings” category (RNS).
2026-05-16 English
Analyst Call - rescheduled
Regulatory Filings Classification · 75% confidence The document contains letters to stock exchanges (BSE & NSE) announcing and rescheduling a quarterly financial results conference call with investors/analysts. It does not provide any actual financial data or the transcript itself, nor is it the publication of a quarterly report. Instead, it is a regulatory announcement of a teleconference schedule. There is no dedicated category for a call invitation, so it falls under the general regulatory announcements (RNS).
2026-05-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.